ORGANIZATION

19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics

September 18, 2018
Nineteen companies have joined the Japan Pharmaceutical Manufacturers Association’s (JPMA) task force on the quality evaluation of nucleic acid therapeutics. The task force, which was set up this spring, includes first and second-tier companies, both Japanese and foreign companies, indicating…

To read the full story

ORGANIZATION

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…